Your browser doesn't support javascript.
loading
HER2+ mCRC patients with exon 20 R784G substitution mutation do not respond to the cetuximab therapy.
Gharib, Ehsan; Salmanipour, Reza; Nazemalhosseini Mojarad, Ehsan; Yaghoob Taleghani, Mohammad; Sarlak, Saharnaz; Malekzade-Moghani, Mona; Nasrabadi, Parinaz Nasri; Meiary, Mohammad Amin; Asadzadeh Aghdaei, Hamid; Zali, Mohammad Reza.
Afiliación
  • Gharib E; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Salmanipour R; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Nazemalhosseini Mojarad E; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Yaghoob Taleghani M; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Sarlak S; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Malekzade-Moghani M; Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Nasrabadi PN; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Meiary MA; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Asadzadeh Aghdaei H; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Zali MR; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Cell Physiol ; 234(8): 13137-13144, 2019 08.
Article en En | MEDLINE | ID: mdl-30549033
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Receptor ErbB-2 / Resistencia a Antineoplásicos / Cetuximab / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Cell Physiol Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Receptor ErbB-2 / Resistencia a Antineoplásicos / Cetuximab / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Cell Physiol Año: 2019 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos